EPC 2025: Updates in Pulmonary Disease

Palm Beach, FL US
September 4, 2025 to September 7, 2025

The Eastern Pulmonary Conference (EPC) plans and organizes an annual CME meeting on clinical topics in Pulmonary Medicine.  With didactic lectures, panel discussions, and problem-based learning (PBL) case discussions, EPC blends the interactivity characteristic of a small regional conference with the relevant information that can improve the diagnostic accuracy and the effectiveness of treatments with practitioners who treat pulmonary diseases.  Physicians, PAs, and NPs are invited to attend.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Eastern Pulmonary Conference (EPC). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 16 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 16 contact hours.

No commercial support was received for this activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…

•    Discuss the risks and benefits of treatment options for pulmonary fibrosis 
•    Identify and refer appropriate patients for lung transplantation
•    Discuss the differential diagnosis and management of pulmonary hypertension due to chronic lung disease
•    Compare bronchodilator treatment options for asthma and COPD
•    Describe the clinical presentations, treatments, and outcomes in patients with pulmonary TB 
•    Incorporate endobronchial ultrasound in the diagnosis of lung diseases
•    Discuss strategies to overcome barriers to lung cancer screening
•    Appropriately prescribe biologic therapy for asthma management
•    Implement the newest guidelines in the management of asthma and COPD
•    Describe how identifying phenotypes of COPD can predict therapeutic responses
•    Educate patients about taping, marijuana, and tobacco safety
•    Optimize management of patients with pulmonary manifestations of neuromuscular weakness
•    Implement recent advances in managing acute respiratory failure in the ICU

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 16.00 AMA PRA Category 1 Credit™
  • 16.00 Attendance
  • 16.00 CBRN
Course opens: 
09/04/2025
Course expires: 
12/31/2025
Event starts: 
09/04/2025 - 12:00pm CDT
Event ends: 
09/07/2025 - 11:00am CDT
Add to calendar: 
Rating: 
0

Eastern Pulmonary Conference 2025
Updates in Pulmonary Disease: Current, Relevant & Interactive
September 4-7, 2025
Palm Beach FL 33480

CME sessions will be held in Ponce 4. 
Breaks and exhibits will be held in the exhibit hall Ponce 5 & 6

Thursday, Sept 4, 2025

3:30 – 4:00 pm Fibrosis: Can we reverse the path? - Ganesh Raghu, MD

4:00 – 4:30 pm More than INH: TB today - Chuck Daley, MD
4:30 – 4:40 pm Panel Discussion: Q & A     

4:40 – 5:50 pm PBL: A 51-year-old woman with COPD and worsening lower extremity edema
Don Bukstein, MD, William Corrao, MD, Ray Davis, MD, Russell Settipane, MD

5:50 – 6:20 pm To treat or not to treat: Pulmonary hypertension due to chronic lung disease - Rachel Damico, MD
6:20 – 6:30 pm    Panel Discussion: Q & A

Friday, Sept 5, 2025

7:45 – 8:15 am Lung transplants: Key lessons and breakthroughs - Gerard Criner, MD

8:15 – 8:45 am It’s all about airflow: The world of bronchodilators - Rey Panettieri, MD
8:45 – 8:55 am Panel Discussion: Q & A

8:55 – 10:00 am PBL: A 52-year-old man with a chronic productive cough
Don Bukstein, MD, Ray Davis, MD, Anas Hadeh, MD, Rey Panettieri, MD, Russell Settipane, MD

10:00 – 10:45 am Coffee Break: Visits exhibits and posters

10:45 – 11:15 am Beyond inhaled antibiotics: Next generation anti-inflammatories in bronchiectasis - Patrick Flume, MD

11:15 – 11:45 am The who, what and when: Pulmonary rehabilitation - Bart Celli, MD
    
11:45 am – 12:15 pm Lung cancer in nonsmokers: A shocking reality - Charles Powell, MD
12:15 – 12:25 pm Panel Discussion: Q & A

1:20 – 1:50 pm Sleep in review 2025 - Richard Millman, MD

1:50 – 2:20 pm All about sonic waves: Endobronchial ultrasound - Momen Wahidi, MD

2:20 – 2:50 pm Lung cancer screening: Controversies & challenges - Charles Powell, MD
2:50 – 3:00 pm Panel Discussion: Q & A

Saturday, Sept 6, 2025

7:45 – 8:45 am Debate: How do we rescue? - Mario Castro, MD, Monica Kraft, MD
8:45 – 8:55 am Panel Discussion: Q & A

8:55 – 10:00 am PBL: A 53-year-old man with frequent bouts of bronchitis
Don Bukstein, MD, Mario Castro, MD, Ray Davis, MD, Rey Panettieri, MD, Russell Settipane, MD

10:00 – 10:45 am Coffee Break: Visit exhibits and posters

10:45 – 11:15 am Biologics in COPD: Selecting the right patient - Bart Celli, MD

11:15 – 11:45 am What is the state of Mab Therapy in asthma and when to stop? - Monica Kraft, MD 

11:45 am – 12:15 pm Asthma treatment goals: Remission vs. modification? - Mario Castro, MD
12:15 – 12:25 pm Panel Discussion: Q & A

1:20 – 1:50 pm Critical care breakthroughs: What’s new? - John Woytanowski, MD

1:50 – 2:20 pm Winning the battle against ICU infections: Preventing VAP, CLABSI & CAUTI - Carla McWilliams, MD
2:20 – 2:30 pm Panel Discussion: Q & A
    
Sunday, Sept 7, 2025

8:00 – 8:25 am Ending respiratory viral infections: The role of vaccines - Carla McWilliams, MD

8:25 – 8:50 am Managing breathing in neuromuscular weakness: Best practices - Loutfi Aboussouan, MD
8:50 – 9:00 am Panel Discussion: Q & A

9:55 – 10:25 am Puff or Pass? The truth about vaping, marijuana, and tobacco safety - Russ Bowler, MD
10:25 – 10:30 am Panel Discussion: Q & A

10:30 – 10:55 am Best practices on billing and coding for pulmonary medicine - Momen Wahidi, MD
10:55 – 11:00 am Panel Discussion: Q & A

The Breakers
One South County Road
Palm Beach, FL 33480
United States

All relevant financial relationships with ineligible companies have been mitigated.

Mario Castro, MD – Speaker
Consultant: Allakos, Amgen, Apogee, Apreo Health, Arrowhead, Pharmaceuticals, AstraZeneca, Connect BioPharma, Enveda, Generate Biomedicines, GSK, Jasper Therapeutics, Kinaset, Om Pharma, Pioneering Medicines, Polarean, Regeneron, Sanofi-Aventis, Teva, Uniquity Bio, Upstream Bio, Verona Pharmaceuticals Researcher: AstraZeneca, Gala Therapeutics, Genentech, GSK, Nocion, Pulmatrix, Regeneron, Sanofi-Aventis Speaker: Amgen, AstraZeneca, Regeneron, Sanofi-Aventis
Stock Options: Aer Therapeutics

Bartolome Celli, MD - Speaker
Consultant: AstraZeneca, Chiesi, Gala, GlaxoSmithKline, Menarini, Roche, Sanofi-Aventis Speaker: GlaxoSmithKline

Gerard Criner, MD – Speaker
Advisor: AstraZeneca, Chiesi, GSK
Researcher: AstraZeneca, Boehringer Ingelheim, Chiesi, GSK

Charles Daley, MD – Speaker
Advisor: AN2, Galagos, GSK, Hyfe, Insmed, Johnson and Johnson, Mannkind, Microbion, MicuRX, Nob Hill, Paratek, Sanofi, Spero
Consultant: AN2, Insmed, Paratek
Researcher: AN2, Insmed, Juvabis, Mannkind, Paratek, Renovion, Spero, Verona

Ray Davis, MD – Speaker
Consultant: AstraZeneca, Grifols, Regeneron, Sanofi
 
Patrick Flume, MD – Speaker
Consultant: Boehringer Ingelheim, Insmed
Researcher: Boehringer-Ingelheim, Insmed, Sanofi, Verona

William Greisner III, MD – Planner, Moderator
Independent Contractor: AstraZeneca, Allakos, GSK, Teva

Anas Hadeh, MD – Speaker
Advisor: Grifols, GSK, Insmed, Sanofi Speaker: AstraZeneca, GSK, Sanofi, Verona

Monica Kraft, MD – Speaker
Advisor: AstraZeneca, Chiesi, Genentech, GSK, Sanofi
Consultant: AstraZeneca, Chiesi, Genentech, GSK, Regeneron, Sanofi Speaker: AstraZeneca, Chiesi, Genentech, GSK, Regeneron, Sanofi

Rey Panettieri, MD – Planner, Speaker, Moderator Advisor: AstraZeneca, Chiesi, Regeneron, Sanofi Researcher: AgoMab AstraZeneca, Genentech, GSK Speaker: AstraZeneca

Charles Powell, MD – Speaker
Consultant: AstraZeneca, BioNTech, Daiichi Sankyo, Duality Biologics, NextCure Inc, OnCusp Therapeutics, Pfizer, Roche, Zai Labs
Research: Archetype Therapeautics

Ganesh Raghu, MD – Speaker
Consultant: Boehringer Ingelheim, Gossamerbio, Bristol Myers Squibb, United Therapeutics, Sanofi, Syndax, Veracyte, Bellerophan, Fibrogen, Nitto, Novartis, Roche, Hoffman, Genentech
DSMB: Avalyn

Russell Settipane, MD – Planner, Reviewer, Speaker, Moderator
Advisor: AbbVie, AstraZeneca, GSK Independent Contractor: Regeneron
Speaker: AbbVie, Amgen, AstraZeneca, Genentech, GSK, Grifols, Regeneron, Sanofi


The following have no relevant financial relationships with ineligible companies to disclose.
Loutfi Aboussouan, MD – Speaker 
Joseph Bellanti, MD – Planner 
Russ Bowler, MD – Speaker
Don Bukstein, MD – Speaker
William Corrao, MD – Planner, Reviewer, Speaker, Moderator 
Rachel Damico, MD – Speaker
Katelyn Loiselle, BSN, RN – Planner 
Ginny Loiselle – Coordinator 
Richard Millman MD – Speaker 
Robert Settipane, MD – Planner 
Momen Wahidi, MD – Speaker
John Woytanowski, MD – Speaker

Available Credit

  • 16.00 AMA PRA Category 1 Credit™
  • 16.00 Attendance
  • 16.00 CBRN
Please login or create an account to take this course.